Angiotensin II (AngII) and the mineralocorticoid receptor (MR) ligand aldosterone both
contribute to cardiovascular disorders, including hypertension and adverse vascular …

In this issue of Circulation Research Jaffe and Mendel-sohn1 show that angiotensin II (Ang
II) directly activates the mineralocorticoid receptor (MR). Using cultured human coronary and …

Inhibition or blockade of the angiotensin-aldosterone system consistently decreases
ischemic cardiovascular events in clinical trials. The steroid hormone aldosterone acts by …

20 Hypertension January 2014 with a smooth muscle cell (SMC)–specific genetic deletion of
the MR demonstrated a blunted age–dependent increase in BP. Furthermore, as compared …

Pathophysiological aldosterone (aldo)/mineralocorticoid receptor (MR) signaling has
significant effects on the cardiovascular system, resulting in hypertension and …

Aldosterone is a key factor in adverse cardiovascular remodeling by acting on the
mineralocorticoid receptor (MR) in different cell types. Endothelial MR activation mediates …

Objective—Vascular remodeling occurs after endothelial injury, resulting in smooth muscle
cell (SMC) proliferation and vascular fibrosis. We previously demonstrated that the blood …

The traditional view of the renin-angiotensin-aldosterone system as a circulating system with
a linear organization, where angiotensin (Ang) II, the final effector peptide of the renin …

The mineralocorticoid receptor (MR) is a key regulator of blood pressure. MR antagonist
drugs are used to treat hypertension and heart failure, resulting in decreased mortality by …

Experimental and clinical studies show that aldosterone/mineralocorticoid receptor (MR)
activation has deleterious effects in the cardiovascular system that may cross-talk with those …